EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gossamer Bio's EBITDA for the
three
months ended in Mar. 2024 was $-37.81 Mil. Gossamer Bio's Revenue for the
three
months ended in Mar. 2024 was $0.00 Mil. Therefore, Gossamer Bio's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.
Gossamer Bio EBITDA Margin % Historical Data
The historical data trend for Gossamer Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Gossamer Bio's EBITDA Margin %
For the Biotechnology subindustry, Gossamer Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gossamer Bio's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gossamer Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gossamer Bio's EBITDA Margin % falls into.
Gossamer Bio EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Gossamer Bio's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gossamer Bio (NAS:GOSS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gossamer Bio EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Gossamer Bio's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GOSS has been successfully added to your 